Chinese Vice President Han Zheng met with Lord Mayor of London Alastair King in Beijing on Tuesday. Han said that the City of London is a world-renowned financial center that has made positive contributions to China-U.K. cooperation in the financial, economic and trade fields.
China and the U.K. are both major economies, and they are highly complementary and have broad prospects for cooperation, Han said. Noting that China's domestic and foreign policies will remain consistent no matter how the world changes, he said China is willing to work with the U.K. as a strategic partner to strengthen communication and cooperation, promote a multi-polar world and economic globalization, implement the important consensus reached between their leaders, and bring more benefits to the two countries and the world at large.
King noted that the U.K. and China have great prospects for cooperation on the green economy, sustainable finance and renewable energy. The City of London welcomes more Chinese companies to do business in London, and stands ready to provide full support and convenience.
Chinese vice president meets with London's lord mayor
Chinese vice president meets with London's lord mayor
China's National Medical Products Administration (NMPA) reviewed a record number of new drug registration applications in 2024, marking a year-on-year increase of 16.2 percent, with antineoplastic drugs accounting for the largest share, according to the administration.
In 2024, the NMPA evaluated a total of 18,259 drug registration applications, a figure that reflects the vitality of China's innovation in drug research and development.
"The record number of reviewed drug applications is a clear sign of China's rapidly growing biopharmaceutical industry. The approval of high-quality new drugs not only gives Chinese patients more and better treatment options, but also shows China's increasing role in the global pharmaceutical market, offering more Chinese solutions to patients around the world," said Yuan Lijia, a staff member at the Center for Drug Evaluation under the NMPA.
Notably, in 2024, applications for clinical trial and market approval of new anti-tumor drugs ranked first among all chemical drugs and biologics, accounting for even half of the total.
"In 2024, anti-tumor drugs made up the largest share of approved clinical trial applications, with over 41 percent being chemical drugs and more than 55 percent being biologics. Throughout the year, anti-tumor drugs also led in the number of innovative drugs approved, with both chemical drugs and biologics surpassing 36 percent," said Geng Ying, an official with the center.
In 2024, China approved the market entry of 48 innovative drugs and 65 innovative medical devices. Its number of drugs in development ranked second globally, and several domestically developed drugs gained approval for global markets.
China's new drug registration applications hit record high in 2024
